Saving Stroke Patients around the world
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
Szukaj
World Recycling Day: Closing the Loop
Transitioning the economy from a linear to a circular approach herculean task – but also an innovation that carries huge potential
Let’s meet the challenge
Together with our partners around the world, we are working on new and innovative solutions for unmet medical need in animal health.
Mechanistic Modeling in Biotherapeutic Drug Development
Mechanistic modeling is revolutionizing biotherapeutic drug development with the goal of getting new medicines to patients faster, more reliably and more cost-effectively.
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Biotherapeutics Discovery
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Behind the Lab
Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
All the same, yet different – Ethnic Equality Month
Mohammed Samy, Human Pharma Marketing Team Lead from Amsterdam explains how ethnic diversity creates collective strength and sustainable growth
Women in STEM 2022
Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.
One step further in fighting rabies in Vietnam
A expedition team set off to the Duc Hue District. The purpose? To vaccinate the entire dog and cat population of several villages.
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
View from Both Sides of the Table
Stawiamy na zarządzanie aliansami
Antibody therapeutics business partnering PetMedix
Combining PetMedix’ expertise in veterinary biotherapeutic technology with Boehringer Ingelheim’s long experience and innovation in human antibody discovery and development provides a unique opportunity for the partners.
Bigger role in ensuring food security
As the world population is projected to reach 9.8 billion in 2050, animal health becomes fundamental to ensure both animal well-being and global protein supply.
Lead with Pride – for the Benefit of All.
How Inclusive Leadership advocates for Acceptance and creating a Sense of Belonging
Equestrian sports technology
Learn about new trends in equine health and get insights into the human-horse relationship!
BI Access to Healthcare Strategy_Availability
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
1990-2022: Wartość dzięki innowacjom
The Boehringer Ingelheim history from 1990 to 2022, with milestones
Our-position
Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
Our Contribution
Humanity is facing serious challenges. We believe we can always do more – for ourselves and for the generations to come.
Boehringer Ingelheim Academy
Find out more about our networking and educational initiative
Kodeks postępowania dostawców
BI’s expectations towards its suppliers on ethical behavior, integrity, professionalism and common business requirements.
Open Innovation at Boehringer Ingelheim
Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
Our Partnering Culture
We embrace the power of partnerships and alliances to find even more breakthrough therapies that change lives.
Mutual benefit: Patient-centricity in clinical trials
Uli Broedl and Bronwyn Lewis share what they learnt from a successful patient organization collaboration on clinical trial design.